Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


50 mg Diclo K IR tablet


Thanks to the Patented Dynamic Buffering Technology (DBT) , tablets 50 mg has the following advantages compared with competing products:

> immediate release profile (Cmax in 27 min. compared to 54 min. of Voltfast)

> regularity of absorption (reduced intra-subject variability in absorption)

> cost competitive manufacturing process (dry mixing for direct compression)




Complete
Non confidential
Opportunity
Profile









Search results